The market expects Arcturus Therapeutics (ARCT) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

View Our Latest Stock Analysis on ARCT Arcturus Therapeutics Stock Performance ARCT stock opened at $10.53 on Friday. The business has a 50-day simple moving average of $13.26 and a two-hundred ...

Arcturus Therapeutics Holdings Inc. ARCT announced ... NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base ...

SAN DIEGO, April 10, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate. Arcturus on Thursday said the designation ...

Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...